Core Insights - The company is focusing on the 'Eton Cares' patient support program to eliminate financial barriers and enhance physician prescribing confidence [1] - Galzin's performance surpassed expectations, achieving 300 active patients within one year by converting users from non-FDA-approved over-the-counter zinc supplements [1] - The acquisition of Hemangiol aligns with a strategy to acquire under-optimized assets and leverage Eton's specialized infrastructure in rare diseases [1] Financial Performance - The adjusted EBITDA margin increased to 29% from 18%, attributed to disciplined cost management and a shift towards higher-margin rare disease assets [2] - Q4 revenue grew by 83% year-over-year, driven by increased sales of Alkindi Sprinkle and contributions from Incralex, Galzan, and Candivy [2] - Revenue is projected to more than double in 2025 following the successful launch of three cornerstone products: Incrolix, Galzyn, and Kinduvi [2] Future Guidance - The company projects revenue exceeding $110 million in 2026 with adjusted EBITDA margins of at least 30% as the portfolio scales [2] - A new goal, '200 by 27,' aims for a $200 million revenue run rate by the end of 2027 through organic growth and at least one additional acquisition [2] - The launch strategy for Desmota includes a 90-day pilot targeting adult endocrinologists, addressing a market three times larger than the pediatric population [2] Long-term Targets - Long-term financial targets include achieving a 50% adjusted EBITDA margin by 2028 and reaching $500 million in annual revenue by 2030 [2] - The R&D pipeline is expected to be highly active in 2026, with five clinical studies planned to support label expansions and new NDAs [2]

Financial Data and Key Metrics Changes - The company's first quarter revenue was $17.3 million, a 117% increase from $8 million in the first quarter of 2024 [35] - Product sales reached $14 million, up 76% from $8 million in the prior year, driven by increased sales of Alkindi Sprinkle and the addition of Incralyx [36] - Adjusted gross profit was $12 million, or 69.5% of total revenue, compared to $5.2 million or 65.6% in the prior year [36] - Adjusted EBITDA for the first quarter was $3.7 million, compared to $500,000 in the prior year [39] - The company reported a net loss of $1.6 million for the quarter, compared to a net loss of $800,000 in the prior year [40] Business Line Data and Key Metrics Changes - Alkindi Sprinkle has shown strong growth for 17 consecutive quarters, with an increase in new patient referrals in 2025 [15] - Incralyx has seen rapid patient acquisition, reaching over 90 active patients shortly after its relaunch, with expectations to reach 100 by year-end [8][12] - Galzin, acquired for Wilson's disease treatment, is expected to generate significant revenue as the company addresses access and affordability issues [21][22] Market Data and Key Metrics Changes - The company is focusing on pediatric endocrinology, leveraging its existing sales force and infrastructure to drive growth in this segment [6][15] - The market for severe primary IGF-1 deficiency is estimated to have around 200 patients in the U.S., with potential for significant growth through increased awareness and screening [6][12] - The Wilson disease market is estimated to impact approximately 10,000 people in the U.S., with only about 2,000 diagnosed and treated, indicating a substantial unmet need [19][20] Company Strategy and Development Direction - The company aims to become a leading player in the ultra-rare disease market, with a strong focus on product launches and pipeline development [30][31] - The strategy includes harmonizing U.S. and EU labels for Incralyx to expand treatment opportunities significantly [10][12] - The company is also advancing new product candidates like ET-700 and ET-800, targeting unmet needs in rare disease treatments [24][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, expecting to exit 2025 with an annual revenue run rate of approximately $80 million [36] - The management team is optimistic about the upcoming product launches and the potential for significant revenue growth from the pipeline [31] - The company is not concerned about tariff impacts, as most products are produced domestically, and any European purchases represent less than 5% of forecasted revenue [33][34] Other Important Information - The company has made significant investments in infrastructure to support growth, including a dedicated metabolic sales team and commercial activities for product relaunches [37][38] - The company expects to maintain adjusted gross margins of approximately 70% for the full year 2025, with long-term goals exceeding 75% by 2028 [36] Q&A Session Summary Question: Update on Incralyx FDA meeting - The meeting request has been submitted, with expectations for a follow-up in July and a submission for label change in Q3 [42] Question: Recent interactions with FDA regarding ET-400 - The company is on track for approval within two weeks, with final labeling discussions underway [44] Question: Weekly Incralyx prescription trends - The company has significantly increased the number of patients, with expectations to exceed revenue goals this year [54][55] Question: Expected timing for ET-400 commercial revenue - The launch is anticipated around June, with revenue expected to ramp up in Q3 [56][57] Question: Commentary on tariff risk exposure - The company does not foresee a meaningful impact from tariff proposals, as it primarily sells domestically [60][62] Question: Feedback on Galzin relaunch - The relaunch has been well-received, with a strong patient uptake and zero copay for patients [68][70]